NasdaqGS - Nasdaq Real Time Price USD

HilleVax, Inc. (HLVX)

Compare

1.6700

+0.1200

+(7.74%)

At close: 4:00:01 PM EDT

1.6700

0.00

(0.00%)

After hours: 4:05:06 PM EDT

GSI Technology And 2 Other Promising Penny Stocks For Your Watchlist

As of April 2025, the U.S. stock market has been experiencing significant volatility, with major indices closing sharply lower amid ongoing concerns about tariffs and their potential economic impact. This turbulent environment has investors seeking opportunities that balance potential growth with stability. Penny stocks, often representing smaller or newer companies, can offer such opportunities by providing access to growth at lower price points. While the term "penny stocks" may seem...

Simply Wall St. 2 days ago

GSIT

HLVX
+7.74%
HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress

$171.4 million of cash, cash equivalents and marketable securities as of December 31, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and other strategic alternatives BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for th

GlobeNewswire 14 days ago

HLVX
+7.74%
US Penny Stocks To Watch In January 2025

As the U.S. stock market navigates a landscape marked by the Federal Reserve's decision to keep interest rates steady, investors remain focused on forthcoming big-tech earnings reports. Amid these broader market dynamics, penny stocks continue to capture attention for their potential to offer affordability and growth opportunities. Despite being considered an outdated term, penny stocks—often representing smaller or newer companies—can still be relevant investment options when supported by...

Simply Wall St. 2 months ago

HUIZ

OVID

HLVX
+7.74%
3 US Penny Stocks With Market Caps Under $100M

As U.S. stocks experience fluctuations amid anticipation of key inflation data and interest rate decisions, investors are keenly observing market movements for potential opportunities. Penny stocks, a term that may seem outdated, continue to capture attention due to their affordability and growth potential, particularly when backed by strong financials. These smaller or newer companies can offer unique value propositions that larger firms might overlook, making them intriguing options for...

Simply Wall St. 3 months ago

HBIO

HLVX
+7.74%
CYCN
HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

$189.3 million of cash, cash equivalents and marketable securities as of September 30, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and other strategic alternatives BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for th

GlobeNewswire 5 months ago

HLVX
+7.74%
Rave Restaurant Group And 2 Other Promising US Penny Stocks

As the U.S. stock market experiences a rise, buoyed by gains in the technology sector and investor focus on the upcoming presidential election, attention is also drawn to smaller investment opportunities. Though often considered a relic from past trading days, "penny stocks" continue to represent potential for significant returns when they are backed by strong financials. This article will explore three such penny stocks that stand out for their balance sheet strength and growth potential in...

Simply Wall St. 5 months ago

RAVE

STIM

HLVX
+7.74%
What Makes HilleVax (HLVX) a New Buy Stock

HilleVax (HLVX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 5 months ago

HLVX
+7.74%
HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

$245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is exploring the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine candidates in adults BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended June 30, 2024 and highlighted recent progress. Recent

GlobeNewswire 7 months ago

HLVX
+7.74%
HilleVax slashes workforce by 40% after norovirus vaccine trial failure

HilleVax’s norovirus vaccine HIL-214 failed to meet key endpoints in its Phase IIb trial in infants, prompting the company to let go of 41 employees.

Pharmaceutical Technology 8 months ago

HLVX
+7.74%
HilleVax Announces Reduction in Force

BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a workforce reduction to reduce its operating expenses. The reduction of approximately 41 employees, or approximately 40% of the company’s workforce, is intended to preserve cash while maintaining core capabilities as the company explores the potential for continued development of its HIL-214 and HIL-216 noro

GlobeNewswire 8 months ago

HLVX
+7.74%
After Plunging -86.93% in 4 Weeks, Here's Why the Trend Might Reverse for HilleVax (HLVX)

The heavy selling pressure might have exhausted for HilleVax (HLVX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks 8 months ago

HLVX
+7.74%
Down -88.84% in 4 Weeks, Here's Why HilleVax (HLVX) Looks Ripe for a Turnaround

HilleVax (HLVX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks 8 months ago

HLVX
+7.74%
Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure

IDEAYA Biosciences (IDYA) and uniQure N.V. (QURE) are in the spotlight following positive pipeline updates.

Zacks 8 months ago

QURE

IDYA

HLVX
+7.74%
HilleVax (HLVX) Tanks as Norovirus Vaccine Study in Infants Fails

HilleVax's (HLVX) phase IIb NEST-IN1 study evaluating HIL-214 for preventing acute gastroenteritis caused by norovirus infection in infants fails to meet its primary efficacy endpoint. Stock falls.

Zacks 8 months ago

HLVX
+7.74%
AVXL
US Equities Markets End Mixed as Investors Await Inflation Data

US Equities Markets End Mixed as Investors Await Inflation Data

PREMIUM
MT Newswires 8 months ago

HLVX
+7.74%
MORF
Sector Update: Health Care Stocks Softer Late Afternoon

Sector Update: Health Care Stocks Softer Late Afternoon

PREMIUM
MT Newswires 8 months ago

LLY

HLVX
+7.74%
HilleVax’s norovirus vaccine ineffective in large trial of infants

Shares in HilleVax plummeted after the company reported its experimental shot failed to meet the primary and secondary goals of the Phase 2b study.

BioPharma Dive 8 months ago

HLVX
+7.74%
HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants

The NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints, and the company will discontinue further development of HIL-214 in infants The company is exploring the potential for continued development of HIL-214 and HIL-216 in adults BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced topline data results from NEST-IN1. NEST-IN1 is a P

GlobeNewswire 8 months ago

HLVX
+7.74%
Director Aditya Kohli Sells 18,000 Shares of HilleVax Inc (HLVX)

On May 22, 2024, Aditya Kohli, Director of HilleVax Inc (NASDAQ:HLVX), executed a sale of 18,000 shares of the company.

GuruFocus.com 10 months ago

HLVX
+7.74%
HilleVax Inc (HLVX) Reports Increased Q1 Losses, Misses Analyst Earnings Expectations

Comprehensive Analysis of HilleVax's First Quarter Financial Performance and Future Outlook

GuruFocus.com 10 months ago

HLVX
+7.74%

Performance Overview

Return	HLVX	S&P 500 (^GSPC)
YTD	-19.32%	-8.81%
1-Year	-88.81%	+3.16%
3-Year	-91.10%	+21.55%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

HilleVax, Inc. (HLVX)

GSI Technology And 2 Other Promising Penny Stocks For Your Watchlist

HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress

US Penny Stocks To Watch In January 2025

3 US Penny Stocks With Market Caps Under $100M

HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Rave Restaurant Group And 2 Other Promising US Penny Stocks

What Makes HilleVax (HLVX) a New Buy Stock

HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

HilleVax slashes workforce by 40% after norovirus vaccine trial failure

HilleVax Announces Reduction in Force

After Plunging -86.93% in 4 Weeks, Here's Why the Trend Might Reverse for HilleVax (HLVX)

Down -88.84% in 4 Weeks, Here's Why HilleVax (HLVX) Looks Ripe for a Turnaround

Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure

HilleVax (HLVX) Tanks as Norovirus Vaccine Study in Infants Fails

US Equities Markets End Mixed as Investors Await Inflation Data

Sector Update: Health Care Stocks Softer Late Afternoon

HilleVax’s norovirus vaccine ineffective in large trial of infants

HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants

Director Aditya Kohli Sells 18,000 Shares of HilleVax Inc (HLVX)

HilleVax Inc (HLVX) Reports Increased Q1 Losses, Misses Analyst Earnings Expectations

Performance Overview